{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:39Z","timestamp":1791924459943,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK110023"],"award-info":[{"award-number":["R01 DK110023"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ekir.2026.107087","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:52:27Z","timestamp":1789746747000},"page":"107087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy"],"prefix":"10.1016","volume":"11","author":[{"given":"Yuzhou","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Mart\u00edn Merinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameron","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee X.","family":"Goodfellow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela F.M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Meyer Horning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney S.","family":"Jellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mandelbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetika","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.107087_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.107087_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/j.ackd.2019.12.003","article-title":"C3 glomerulopathy: pathogenesis and treatment","volume":"27","author":"Ahmad","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2026.107087_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2024.1460146","article-title":"C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation","volume":"4","author":"Heidenreich","year":"2024","journal-title":"Front Nephrol"},{"key":"10.1016\/j.ekir.2026.107087_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107087_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2026.107087_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107087_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ekir.2023.11.025","article-title":"Defining nephritic factors as diverse drivers of systemic complement dysregulation in C3 glomerulopathy","volume":"9","author":"Hauer","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107087_bib8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfae245","article-title":"Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGN","volume":"40","author":"Meuleman","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.107087_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/ndt\/gfae243","article-title":"Acquired and genetic drivers of C3 and C5 convertase dysregulation in C3 glomerulopathy and immunoglobulin-associated MPGN","volume":"40","author":"Roquigny","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.107087_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery","volume":"38","author":"Mastellos","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ekir.2026.107087_bib11","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ekir.2023.04.029","article-title":"Design and rationale of the APPELHUS Phase 3 open-label study of factor B inhibitor iptacopan for atypicalhemolytic uremic syndrome","volume":"8","author":"Kavanagh","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107087_bib12","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107087_bib13","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107087_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2024.10.023","article-title":"Iptacopan reduces proteinuria and stabilizes kidney function in C3 glomerulopathy","volume":"10","author":"Nester","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107087_bib15","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.107087_bib16","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a Phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107087_bib17","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMe2515157","article-title":"Pegcetacoplan for treatment of C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Zand","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107087_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1515\/cclm-2025-1270","article-title":"Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan","volume":"64","author":"Langemeijer","year":"2026","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ekir.2026.107087_bib19","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107087_bib20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.107087_bib21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2215\/CJN.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107087_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","article-title":"C4 nephritic factors in C3 glomerulopathy: acase series","volume":"70","author":"Zhang","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.107087_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107087_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1723596","article-title":"C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria","volume":"16","author":"Rodriguez de Cordoba","year":"2025","journal-title":"Front Immunol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492603319X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492603319X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:11:30Z","timestamp":1791922290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492603319X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S246802492603319X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107087","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"107087"}}